Human VEGF R2, His Tag (KDR-H5227) is expressed from human 293 cells (HEK293). It contains AA Ala 20 - Glu 764 (Accession # AAI31823.1).
Predicted N-terminus: Ala 20
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 85.2 kDa. The protein migrates as 105-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human VEGF R2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Human VEGF R2, His Tag (Cat. No. KDR-H5227) was greater than 90% as determined by SEC-HPLC.
Immobilized Human VEGF165, Tag Free (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Human VEGF R2, His Tag (Cat. No. KDR-H5227) with a linear range of 10-156 ng/mL (QC tested).
Immobilized Human VEGF R2, His Tag (Cat. No. KDR-H5227) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a linear range of 2-39 ng/mL (QC tested).
Immobilized Human VEGF R2, His Tag (Cat. No. KDR-H5227) at 2 μg/mL (100 μL/well), can bind pre-mixed increasing concentrations of Bevacizumab and 0.05 μg/mL (100 μL/well) Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a half maximal inhibitory concentration (IC50) of 0.74 μg/mL (Routinely tested).
Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.